$BMEA
Biomea Fusion, Inc.

2023 Q4 Form 10-K Financial Statement

#000095017024038026 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.462M $23.59M
YoY Change 12.64% 12.75%
% of Gross Profit
Research & Development $30.87M $102.5M
YoY Change 50.28% 63.52%
% of Gross Profit
Depreciation & Amortization $415.0K $1.515M
YoY Change 129.28% 116.43%
% of Gross Profit
Operating Expenses $37.33M $126.1M
YoY Change 42.06% 50.82%
Operating Profit -$37.33M -$126.1M
YoY Change 42.06% 50.82%
Interest Expense $2.444M $8.880M
YoY Change 154.05% 391.69%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$34.88M -$117.3M
YoY Change 37.81% 43.29%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$34.88M -$117.3M
YoY Change 37.81% 43.29%
Net Earnings / Revenue
Basic Earnings Per Share -$0.98 -$3.44
Diluted Earnings Per Share -$0.98 -$3.44
COMMON SHARES
Basic Shares Outstanding 35.71M 34.11M
Diluted Shares Outstanding 35.75M 34.11M

Balance Sheet

Concept 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $176.9M $176.9M
YoY Change 56.45% 56.45%
Cash & Equivalents $176.9M $176.9M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $2.315M $2.315M
YoY Change -51.47% -51.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $179.2M $179.2M
YoY Change 52.08% 52.08%
LONG-TERM ASSETS
Property, Plant & Equipment $14.87M $14.87M
YoY Change 154.63% 86.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $5.873M $5.873M
YoY Change 67.99% 67.99%
Total Long-Term Assets $20.75M $20.75M
YoY Change 80.59% 80.59%
TOTAL ASSETS
Total Short-Term Assets $179.2M $179.2M
Total Long-Term Assets $20.75M $20.75M
Total Assets $199.9M $199.9M
YoY Change 54.61% 54.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.851M $6.851M
YoY Change 0.37% 0.37%
Accrued Expenses $15.82M $15.82M
YoY Change 35.9% 35.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.86M $22.86M
YoY Change 19.68% 19.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.830M $7.830M
YoY Change 369.71% 369.71%
Total Long-Term Liabilities $7.830M $7.830M
YoY Change 369.71% 369.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.86M $22.86M
Total Long-Term Liabilities $7.830M $7.830M
Total Liabilities $30.69M $30.69M
YoY Change 47.78% 47.78%
SHAREHOLDERS EQUITY
Retained Earnings -$248.8M
YoY Change 89.08%
Common Stock $4.000K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $169.2M $169.2M
YoY Change
Total Liabilities & Shareholders Equity $199.9M $199.9M
YoY Change 54.61% 54.61%

Cashflow Statement

Concept 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$34.88M -$117.3M
YoY Change 37.81% 43.29%
Depreciation, Depletion And Amortization $415.0K $1.515M
YoY Change 129.28% 116.43%
Cash From Operating Activities -$22.83M -$96.59M
YoY Change 13.02% 54.75%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $3.370M
YoY Change -98.6% 227.18%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.150M
YoY Change -100.0% -95.95%
Cash From Investing Activities -$10.00K -$2.220M
YoY Change -98.57% -108.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $163.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 618.0K 163.8M
YoY Change 26.12% 13120.18%
NET CHANGE
Cash From Operating Activities -22.83M -96.59M
Cash From Investing Activities -10.00K -2.220M
Cash From Financing Activities 618.0K 163.8M
Net Change In Cash -22.22M 64.99M
YoY Change 8.88% -292.06%
FREE CASH FLOW
Cash From Operating Activities -$22.83M -$96.59M
Capital Expenditures $10.00K $3.370M
Free Cash Flow -$22.84M -$99.96M
YoY Change 9.22% 57.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001840439
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration
PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40335
CY2023 dei Entity Registrant Name
EntityRegistrantName
Biomea Fusion, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2520134
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
900 Middlefield Road, 4th Floor
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
980-9099
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2023 dei Trading Symbol
TradingSymbol
BMEA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
596910000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35889360
CY2023 dei Auditor Firm
AuditorFirmId
34
CY2023 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, CA
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176866000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111899000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
1150000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2315000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4770000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
179181000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
117819000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5159000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5841000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
370000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5503000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3145000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9714000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2151000
CY2023Q4 us-gaap Assets
Assets
199927000
CY2022Q4 us-gaap Assets
Assets
129307000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6851000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6826000
CY2023Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13543000
CY2022Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11657000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2466000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
618000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22860000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19101000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7830000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1667000
CY2023Q4 us-gaap Liabilities
Liabilities
30690000
CY2022Q4 us-gaap Liabilities
Liabilities
20768000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35866610
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35866610
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29561554
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29561554
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
418058000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
240107000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248825000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131570000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
169237000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108539000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
199927000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129307000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102546000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62713000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27996000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23589000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20921000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13671000
CY2023 us-gaap Operating Expenses
OperatingExpenses
126135000
CY2022 us-gaap Operating Expenses
OperatingExpenses
83634000
CY2021 us-gaap Operating Expenses
OperatingExpenses
41667000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-126135000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-83634000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41667000
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
8880000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
1806000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
100000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117255000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-81828000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41567000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117254000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81819000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41577000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.44
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.44
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34106923
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34106923
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271777
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271777
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23858552
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23858552
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5169000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
55735000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
254000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6234000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41567000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
178783000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
516000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
723000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10336000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-81828000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
108539000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
937000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1081000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14131000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117255000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
169237000
CY2023 us-gaap Profit Loss
ProfitLoss
-117255000
CY2022 us-gaap Profit Loss
ProfitLoss
-81828000
CY2021 us-gaap Profit Loss
ProfitLoss
-41567000
CY2023 us-gaap Depreciation
Depreciation
1515000
CY2022 us-gaap Depreciation
Depreciation
691000
CY2021 us-gaap Depreciation
Depreciation
249000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2686000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
571000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
704000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
14131000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
10336000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
6234000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-144000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-516000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2478000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1725000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2517000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2358000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1915000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1218000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2562000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2960000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
640000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1886000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8914000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2110000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2238000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-565000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-589000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-96592000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62417000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35438000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3370000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1030000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3171000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
38492000
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1150000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
28371000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8308000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2220000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27341000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33355000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161803000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
152753000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1995000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1239000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
468000
CY2021 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-36000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163798000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1239000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153185000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
64986000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33837000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84392000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146087000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61695000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177236000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146087000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5971000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3216000
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
2537000
CY2023 bmea Remeasurement Of Operating Lease Right Of Use Assets And Lease Liability
RemeasurementOfOperatingLeaseRightOfUseAssetsAndLeaseLiability
5668000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176866000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111899000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145736000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
370000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
351000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177236000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112250000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146087000
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000
CY2023Q2 bmea Stock Issued During Period In Connection With Underwriters Exercise Of Over Allotment Option
StockIssuedDuringPeriodInConnectionWithUnderwritersExerciseOfOverAllotmentOption
750000
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
30
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161800000
CY2023Q2 bmea Underwriting Discounts Commissions And Offering Costs
UnderwritingDiscountsCommissionsAndOfferingCosts
10700000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248800000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
177200000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to clinical and preclinical accruals,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accruals, fair value of common stock, stock-based compensation, operating lease right-of-use (ROU) assets and liabilities and income taxes. The Company bases its estimates on its historical experience and also on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></p>
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk, consist primarily of cash, cash equivalents and investments. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company invests in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate notes, commercial paper, and asset backed securities. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded in the balance sheet. The Company’s investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate notes and commercial paper, and places restrictions on the credit ratings, maturities and concentration by type and issuer. The Company has not experienced any losses on its deposits of cash, cash equivalents and investments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span></p>
CY2023 bmea Number Of Stand By Letters Of Credit Consisted In Restricted Cash
NumberOfStandByLettersOfCreditConsistedInRestrictedCash
2
CY2023 bmea Property Plant And Equipment Estimated Remaining Useful Life
PropertyPlantAndEquipmentEstimatedRemainingUsefulLife
Shorter of remaining lease term or estimated useful life
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42071000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3471556
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.87
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2023Q4 bmea Fair Value Asset Level1 To Level2 Transfer Amount
FairValueAssetLevel1ToLevel2TransferAmount
0
CY2023Q4 bmea Fair Value Asset Level2 To Level1 Transfer Amount
FairValueAssetLevel2ToLevel1TransferAmount
0
CY2023Q4 bmea Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2023Q4 bmea Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174429000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
174429000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106835000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106834000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1200000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023 bmea Impairment Loss On Investments Available For Sale Securities
ImpairmentLossOnInvestmentsAvailableForSaleSecurities
0
CY2022 bmea Impairment Loss On Investments Available For Sale Securities
ImpairmentLossOnInvestmentsAvailableForSaleSecurities
0
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7590000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6757000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2431000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
916000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5159000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5841000
CY2023 us-gaap Depreciation
Depreciation
1500000
CY2022 us-gaap Depreciation
Depreciation
700000
CY2021 us-gaap Depreciation
Depreciation
200000
CY2023Q4 bmea Accrued Research And Development Materials And Services
AccruedResearchAndDevelopmentMaterialsAndServices
6952000
CY2022Q4 bmea Accrued Research And Development Materials And Services
AccruedResearchAndDevelopmentMaterialsAndServices
6039000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5956000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4774000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
443000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
208000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
192000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
636000
CY2023Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13543000
CY2022Q4 bmea Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11657000
CY2023Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8720898
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7483830
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
27600000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5341975
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.79
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6875000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2441795
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.66
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
125192
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.48
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300971
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.14
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7357607
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.34
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
20783000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.799
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.931
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.91
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.031
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.57
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.25
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.28
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.111
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.005
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.041
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.002
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.015
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Amortization
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization
0.026
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.346
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.215
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.227
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31469000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12100000
CY2023Q4 bmea Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
25055000
CY2022Q4 bmea Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
10326000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1562000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
411000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4602000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1887000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1607000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1129000
CY2023Q4 bmea Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2857000
CY2022Q4 bmea Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
480000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7400000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1633000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
74552000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27966000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
71512000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27432000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3040000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
534000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
344000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
82000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
2696000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
452000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3040000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
534000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
44200000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17700000
CY2023 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
In general, an “ownership change” will occur if there is a cumulative change in the Company's ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Therefore, certain of the Company's carryforward tax attributes may be subject to an annual limitation regarding their utilization against taxable income in future periods. The Company has performed a Section 382 study and has concluded that ownership changes have occurred
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
624000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
112000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
227000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
133000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1365000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
379000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
111000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2216000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
624000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
112000
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Significant Change In Unrecognized Tax Benefits Nature Of Event
SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent
The Company does not expect the unrecognized tax benefits to change significantly over the next twelve months.
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
There are currently no pending income tax examinations.
CY2023 bmea Reimbursement On Additional Lease Payments
ReimbursementOnAdditionalLeasePayments
400000
CY2023 bmea Lease Term Annual Interest Rate
LeaseTermAnnualInterestRate
0.07
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
2469000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
346000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
4099000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
711000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
482000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2921000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
671000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
1326000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
357000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
105000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.054
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4054000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2757000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1380000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1431000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1474000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4826000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15922000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4488000
CY2023Q4 bmea Tennant Improvement Allowance Yet To Be Received
TennantImprovementAllowanceYetToBeReceived
1138000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
10296000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2466000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7830000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
10296000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
30031000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
27657000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
31119000
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
37328000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30031000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27657000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-117255000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-81828000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41567000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34106923
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34106923
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271777
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271777
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23858552
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23858552
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.44
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.44
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.8
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.8
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7501172
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5651866
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4754960
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24395000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21938000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25347000
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30866000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5636000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5719000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5772000
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6462000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31119000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-37328000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
980000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
2766000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
2690000
CY2023Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
2444000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29051000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24891000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-28429000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-34884000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29586468
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29586468
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35348293
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35348293
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35653988
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35653988
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35754165
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35754165
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11350000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12582000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18242000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20539000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5050000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4892000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5242000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5737000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
16400000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17474000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
23484000
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
26276000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16400000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17474000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23484000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-26276000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
34000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
216000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
594000
CY2022Q4 us-gaap Interest And Other Income
InterestAndOtherIncome
962000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16366000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17258000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-22890000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-25314000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29126088
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29126088
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29196398
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29196398
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29319042
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29319042
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29441596
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29441596

Files In Submission

Name View Source Status
0000950170-24-038026-index-headers.html Edgar Link pending
0000950170-24-038026-index.html Edgar Link pending
0000950170-24-038026.txt Edgar Link pending
0000950170-24-038026-xbrl.zip Edgar Link pending
bmea-20231231.htm Edgar Link pending
bmea-20231231.xsd Edgar Link pending
bmea-ex10_5c.htm Edgar Link pending
bmea-ex21_1.htm Edgar Link pending
bmea-ex23_1.htm Edgar Link pending
bmea-ex31_1.htm Edgar Link pending
bmea-ex31_2.htm Edgar Link pending
bmea-ex32_1.htm Edgar Link pending
bmea-ex32_2.htm Edgar Link pending
bmea-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img4174500_0.jpg Edgar Link pending
img4174500_1.jpg Edgar Link pending
img4174500_10.jpg Edgar Link pending
img4174500_11.jpg Edgar Link pending
img4174500_12.jpg Edgar Link pending
img4174500_13.jpg Edgar Link pending
img4174500_14.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bmea-20231231_htm.xml Edgar Link completed
img4174500_15.jpg Edgar Link pending
img4174500_16.jpg Edgar Link pending
img4174500_17.jpg Edgar Link pending
img4174500_18.jpg Edgar Link pending
img4174500_19.jpg Edgar Link pending
img4174500_2.jpg Edgar Link pending
img4174500_20.jpg Edgar Link pending
img4174500_21.jpg Edgar Link pending
img4174500_22.jpg Edgar Link pending
img4174500_23.jpg Edgar Link pending
img4174500_24.jpg Edgar Link pending
img4174500_25.jpg Edgar Link pending
img4174500_3.jpg Edgar Link pending
img4174500_4.jpg Edgar Link pending
img4174500_5.jpg Edgar Link pending
img4174500_6.jpg Edgar Link pending
img4174500_7.jpg Edgar Link pending
img4174500_8.jpg Edgar Link pending
img4174500_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending